ALLOGRAFT rejection is a complex process, which requires interactions between different cell types and a variety of soluble factors, such as cytokines. In this review we discuss the role of cytokines in the induction and effector phases of the rejection process and in the induction and maintenance of allospecific graft tolerance. Furthermore, we discuss the feasibility of clinical graft function monitoring by measuring cytokines and the possibilities for intervention in the cytokine network in order to inhibit graft rejection and eventually obtain graft acceptance.

Key words: Cytokines, Graft rejection, Monoclonal antibody treatment, Th1–Th2 subsets, Tolerance

Cytokines in clinical and experimental transplantation

Ann C. T. M. Vossen and Huub F. J. Savelkoul

Department of Immunology, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands

CA Corresponding Author

Introduction

Cytokines are proteins, which act as soluble mediators and regulators of immune responses. They perform their actions by binding to specific membrane-bound receptors and act in a paracrine or autocrine fashion. Different cell types, not only leukocytes, can produce the same cytokine or react to the same cytokine. So, one cytokine can have a range of differential effects on various different target cells (pleiotropy). Furthermore, two different cytokines can have the same effect (redundancy). Cytokines are able to positively or negatively influence the production and function of one another. The complexity of the cytokine network should be kept in mind, while interpreting experimental or clinical findings as discussed in this review.

One of the immune responses in which cytokines are considered to play an important role is allograft rejection. The process of rejection has been studied carefully and starts to become more clear.1-3 During the induction phase of rejection, T-cell receptor (TCR) recognition of the foreign MHC molecule results in T-cell activation, expression of the interleukin (IL)-2 receptor (R) and production IL-2, which in an autocrine fashion induces clonal expansion of the activated T cells. During T cell activation, soluble sIL-2R are released.4 It is thought that CD4+ T lymphocytes are essential for initiation of graft rejection and CD8+ T cells are more important in the effector phase of rejection.3 In this phase, production of IL-2 and other cytokines induces influx and proliferation of CD8+ cytotoxic T cells, natural killer (NK) cells and macrophages. This inflammatory process will lead to tissue destruction and dysfunction of the graft. Cytokines can influence this process at several levels (Table 1). IL-1, produced by macrophages, acts as an accessory signal from the antigen presenting cell (APC) for T cell proliferation.6 IL-2 is a growth factor for T lymphocytes, induces T lymphocyte cytotoxicity and stimulates NK cell activity.9 Interferon (IFN)-γ activates macrophages, cytotoxic T cells and NK cells and induces increased expression of MHC class I and II molecules in this way increasing the allogenicity of the graft.9 Tumour necrosis factor (TNF)-α increases the MHC class I expression and activates neutrophils.10-12 Apart from these activities, cytokines may have direct cytotoxic effects on the grafted tissue.13

Since CD4+ T cells are of such importance for graft rejection, T-helper (Th)1–Th2 subsets have been studied for their potential role in regulating the rejection process. Both in mice and in human, different Th cell clones have been described, which can be distinguished by the different sets of cytokines they produce.14,15 Th1 cells produce IL-2, IFN-γ and

| Table 1. Cell sources of cytokines relevant in transplantation |
|---------------------------------------------------------------|
| **CTL** | **Th1** | **Th2** | **NK** | **B cell** | **Monocytes/macrophages** | **Others** |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| IL-1 | + | + | + | + | + | + |
| IL-2 | + | + | + | + | + | + |
| IL-4 | + | + | + | + | + | + |
| IL-5 | + | + | + | + | + | + |
| IL-6 | + | + | + | + | + | + |
| IL-10 | + | + | + | + | + | + |
| IFN-γ | + | + | + | + | + | + |
| TNF-α | + | + | + | + | + | + |
| TNF-β | + | + | + | + | + | + |

*CTL, cytotoxic T lymphocytes.
Other cells producing these cytokines are fibroblasts, epithelial cells etc.
lymphotoxin (LT, also known as TNF-β), while Th2 cells produce IL-4, IL-5, IL-6 and IL-10. Other cytokines, such as IL-3 and TNF-α, are produced by both Th subsets.

Different functions have been assigned to the different Th subsets. Th1 cells mediate delayed-type hypersensitivity (DTH), anti-viral and anti-tumoral cytotoxic effects, while Th2 cells provide help for B cell differentiation and antibody formation. These two Th subsets are able to influence each others cytokine production and proliferation. IFN-γ, produced by Th1 cells, inhibits Th2 cell proliferation and cytokine production. IFNγ also antagonizes the activity of IL-4 in B cell activation and isotype production. The Th2 cytokine IL-10, inhibits the production of Th1 cytokines while IL-4 inhibits Th1 cell proliferation. Since cellular cytotoxicity plays an important role in allograft rejection, Th1 cells are thought to dominate in this process. On the other hand, the suppression of these allospecific Th1 cells by Th2 cells could be a mechanism of graft acceptance. Altered cytokine gene expression and production during graft rejection provides a logical target to redirect the observed shifts in the Th1–Th2 balance interfering with the cytokine network.

To further elucidate the role of cytokines in clinical and experimental allograft rejection and survival, we first focus on the detection of cytokines during the rejection process and during graft acceptance. Then we describe the approaches that have been used to interfere in the cytokine network and future prospects for therapeutic intervention.

**Detection of cytokines during graft rejection**

There are two reasons for detecting cytokines during allograft rejection. The first is to find a reliable and preferably non-invasive method to monitor graft function. If certain cytokines are found to be early predictors of acute rejection this enables us to start rejection therapy as soon as possible and to monitor the success of this therapy. The second reason is to learn more about which cytokines play a role in the rejection process and therefore might be good targets for immunomodulation. We think that therapeutic intervention in the earliest (induction) phase of rejection is preferable to intervention in the effector phase in order to redirect the immune response and achieve long-term allograft survival. Therefore, we consider cytokines appearing in the induction phase of more importance to serve as targets for immunomodulation than cytokines appearing late in rejection.

The advantage of animal models for graft rejection is that proper controls, including syngeneic grafts and non-grafted tissue can be examined for cytokine expression. Furthermore, in general, no immunosuppressive drugs are being used in these models.

In the clinical setting, immunosuppressive drugs are routinely used for the prevention of organ transplant rejection. Immunosuppressive drugs like cyclosporin A (CsA) and glucocorticoids can inhibit TNF and IL-6 production, while the anti-CD3 mAb OKT3 and anti-thymocyte globulin (ATG) can increase serum IL-6 and TNF-α levels.

Table 2 summarizes the cytokines described to be involved in allograft rejection.

**Detection of systemic cytokines**: In the clinical setting a lot of effort has been made to find a single or few cytokines in the serum, urine or bile, that permit monitoring graft rejection. In kidney, liver or lung transplantation, serum levels of IL-6, IL-2, TNF-α, IL-2, and sIL-2R have been shown to increase in relation to graft rejection. Serial monitoring was necessary, since not the absolute levels of IL-6 or sIL-2R, but rather a rise of these levels indicated the development of rejection. However, the measured cytokine levels have low sensitivity and specificity regarding rejection diagnosis. TNF-α, IL-2 and sIL-2R levels were found to be elevated in some cases of stable graft function. IL-6, TNF-α and sIL-2R levels were increased in the early postoperative period and elevations of IL-6, TNF-α or sIL-2R levels were found during episodes of infection. Yoshimura *et al.* suggested that serum IL-6 levels or even better the ratio of IL-6 to CsA trough value may discriminate rejection from CsA nephrotoxicity. Possibly, measurements of TNF-α or IL-2 in the urine of renal allograft recipients or IL-6 in the bile, as shown in a rat hepatic allograft model, will have more value in discriminating allograft rejection from infection or non-immunological graft dysfunction. These studies demonstrate that systemic cytokine measurements are not reliable enough to differentiate rejection from infection. Therefore, they cannot be used for monitoring and histological tissue analysis remains the standard for diagnosis of rejection. Whether these cytokines are involved in the mechanism of allograft rejection, as has been suggested in a few of the above-mentioned studies, is in our opinion doubtful. Based on their paracrine and autocrine activity, the detection of cytokines in the periphery is not likely to reflect the local activities within the graft. It is much more likely that cytokines

| Cytokines | References |
|-----------|------------|
| Systemic | IL-2, sIL-2R, IL-6, TNF-α | 23, 25–35 |
| In situ animal models | IL-2, IL-4, (IFN-γ), (TNF-β) | 44, 45 |
| In situ clinical transplantation | IL-2, IL-5, IL-6, IFN-γ, TNF-α | 46–50 |
that are systemically present, such as TNF-α and IL-6 are involved in the inflammatory process of an ongoing rejection process and are rather nonspecific markers in the serum. Interference with these cytokines could diminish the development of inflammation, but a more preferable target for immunomodulation would be those particular cytokines, that are involved in the induction phase of the local rejection process in order to create a new immunological balance and graft acceptance.

In situ detection of cytokines during graft rejection: In order to get more insight into which cytokines are involved in the rejection process, cytokines have been detected in the graft in experimental and clinical settings. For in situ detection of cytokines several techniques have been used. Northern blot analysis, reverse transcription (RT)-PCR and in situ hybridization were used to detect cytokine mRNA within the graft. In sponge matrix allografts, i.e. sponges containing allogeneic cells, the exudate was tested for cytokine proteins. Furthermore, the local production of cytokines was investigated using immunohistochemistry or cultures of graft-infiltrating cells (GIC). All of these techniques have their own advantages and disadvantages. For example, if cytokine mRNA is to be detected, one cannot conclude that the protein is also present, since the production of cytokines can be regulated at post-transcriptional level. In situ hybridization indicates the localization of cytokine production and is also rather sensitive, but is a difficult and time-consuming technique. RT-PCR is an extremely sensitive method, but this method gives no information about the cell-type that produces the detected cytokines. Immunohistochemistry is able to demonstrate the cytokine-producing cells. However, most cytokines are not retained in the cytosol, but are directly secreted after translation. This may cause false negative results. On the other hand, it is difficult to discriminate between the cytokine producing cells and the target cells for these cytokines. Especially interpretations concerning Th1–Th2 imbalances should be made very carefully. This also counts if cytokines are detected in supernatants of cultured graft infiltrating cells. It has been shown that culture conditions, such as added cytokines, can dictate the outcome of the cytokine pattern produced. The analysis of mRNA of cultured cells is also unreliable, since manipulating the cells can cause not only induction of a particular cytokine mRNA, but also the level of unstable cytokine mRNA to decline.

Two studies in a murine cardiac allograft model used the extremely sensitive reverse transcription PCR method to detect cytokine mRNA in normal tissue, isografts and allografts at several days after grafting. Their results were quite similar. The cytokines that were detectable could be divided into three groups. The first group of cytokines can be detected in normal tissue, isografts and allografts and consists of IL-1β, IL-5, IL-6, TNF-α and TGF-β. The second group, including IL-1α and IL-3, is expressed in both isografts and allografts. These two groups seem to represent cytokines which are induced in response to the grafting procedure and are not correlated with the rejection process itself. The last and probably the most important group consists of IL-2 and IL-4. These cytokines are only present in allografts, which suggests they play a role in allograft rejection. However, the two studies show inconsistent data on two cytokines, TNF-β and IFN-γ. Dallman et al. showed that TNF-β can only be detected in allografts, while Morgan et al. also detected this cytokine in isografts. IFN-γ, however, was only found in allografts by Morgan et al., while Dallman et al. detected IFN-γ mRNA in normal tissue and in isografts as well, though the levels were lower than in the allografts. This difference in cytokine pattern remains unexplained. Interestingly, Dallman et al. found that IL-2, IL-4 and TNF-β, the cytokines that are expressed only in the allografts, were all transcribed transiently, their expression being maximal at 4–5 days after transplantation. Thereafter the expression declined before clinical signs of rejection appeared, suggesting these cytokines play a role in the initiation of rejection.

In the clinical setting in situ detection of cytokines in rejecting allografts has been compared with grafts without signs of rejection. In situ hybridization of human renal biopsies showed that normal kidney tissue or biopsies from patients with stable graft function do not significantly express IL-6, TNF-α or IFN-γ transcripts. During acute rejection, however, the grafts showed significant levels of IL-6 mRNA, but not TNF-α or IFN-γ mRNA. The IL-6 mRNA was expressed in many different cell types, such as glomerular cells, tubular epithelium and vascular endothelium. The significance of the IL-6 production by these nonimmune cells remains unclear. Using the same technique on irreversibly rejected kidney grafts, TNF-α mRNA could be detected in macrophage-like infiltrating cells. Immunohistochemistry showed that these cells actually produced TNF-α protein. Glomerular cells and tubular epithelium cells probably were target cells for TNF-α, since TNF-α protein could be detected, but no TNF-α mRNA was found in these cells. The results of mRNA detection during allograft rejection may be influenced by the organ investigated. In human liver allografts IL-1β, IL-4, IL-6 and TNF-α mRNA was expressed in rejecting allografts and in grafts without signs of rejection. Only IL-5 mRNA was associated with liver graft rejection. All the above-mentioned data are derived from grafts, in which the rejection process had developed quite far, as graft dysfunction was already apparent, and the rejection sometimes even irreversible. So, the
cytokines detected may play a role in the graft rejection, but may also be rather nonspecific mediators of tissue inflammation and destruction. Two studies, using RT-PCR on fine-needle aspirates, were able to detect IL-2 mRNA and IFN-γ mRNA in samples, taken before clinical rejection. Since the expression was transient, sequential analysis is required to use this method to predict graft rejection.

**Detection of cytokines during allograft acceptance:** In animal models, the induction of allograft tolerance has succeeded by using several different protocols, such as a preoperative donor-specific transfusion (DST) or anti-CD4 monoclonal antibody (mAb) treatment. Determination of the changes in the cytokine profile in these accepted grafts compared with rejecting allografts, may clarify the mechanism by which this state of tolerance is maintained and may indicate ways to manipulate the immune system in order to obtain tolerance. Strangely, intragraft events, which have been ascribed to cytokines, such as mononuclear cell infiltration, allospecific cytotoxic T cells and elevated expression of MHC class I and II antigens, are still apparent in tolerized grafts and renal allografts with stable graft function.

In a rat kidney allograft model, in which tolerance was induced by DST, graft infiltrating cells from tolerant rats were unable to produce IL-2 *in vitro*, expressed lower levels of the IL-2R and showed lower proliferation in response to IL-2 than cells from untreated rats. In a comparable model, tolerized rat heart allografts showed a lower expression of IL-2 and IFN-γ mRNA and a different kinetics of these messages than rejecting allografts. Strong evidence that the downregulation of IL-2 or IFN-γ mRNA plays a role in the development of graft tolerance is provided by the fact that simultaneous administration of IL-2 or IFN-γ and the DST abrogates the tolerizing effect. It is still unclear whether this downregulation of Th1 cytokines is the mechanism of tolerance induction or whether Th2 cells play a role in suppressing these Th1 cytokines.

After induction of tolerance, using several different strategies, it has been shown that IL-2 and IFN-γ mRNA were downregulated, whereas IL-4 and IL-10 (Th2 cytokines) mRNA expression remained at the same level or even increased. However, there is no proof that the source of these cytokines is indeed T lymphocytes. Recently, it has been shown, that IL-10 mRNA is detectable in many organs of a normal mouse and is expressed at the same level in nude mice or SCID mice, suggesting independence of T and B cells.

Anti-CD4 mAb treatment has resulted in graft acceptance in several animal models. Partial depletion of CD4+ T cells in mice resulted in a higher expression of IL-4 mRNA and a lower expression of IFN-γ mRNA, as detected by *in situ* hybridization in purified CD4+ T cells. In other studies, using anti-CD4 mAb, long term renal allograft survival and abrogation of accelerated cardiac rejection were accompanied by diminished IL-2 expression and preserved IL-4 expression, suggesting that the Th1-Th2 dichotomy does play a role in immunosuppression. Additional evidence is provided by the finding that adoptive transfer of a bm12-specific Th2 cell line to B6 mice resulted in prolongation of bm12 skin grafts, whereas BALB/c third party grafts were rejected. It is interesting to note that IL-4 can be detected both early in the rejection process and during graft acceptance. This finding awaits further clarification.

**Strategies interfering with cytokine effects**

CsA and FK506 are important immunosuppressive drugs, that are widely used for preventing organ allograft rejection. It is known for several years now that their immunosuppressive mechanism is based on inhibition of T cell signal transduction pathways leading to activation of cytokine gene expression. Besides these established regimens, alternative ways to interfere with cytokine effects have been studied (Table 3).

**Monoclonal or polyclonal antibodies:** Since cytokines have been shown to be associated with allograft rejection, several strategies have been studied to interfere with cytokine function in order to prolong graft survival.

Monoclonal and polyclonal antibodies against cytokines have been shown to prolong allograft survival in several animal models. Anti-IFN-γ mAb blocked MHC class II disparate skin graft rejection in mice, but had no effect on MHC class I disparate skin graft rejection. Anti-IL-2, anti-TNF-α and anti-LT antibodies were able to prolong rat cardiac allograft survival, when given as the only therapy. In the same model, anti-IFN-γ antibodies alone failed to prolong graft survival compared with untreated controls. However, in combination with CsA, anti-IFN-γ antibodies prolonged allograft survival in a synergistic way. This synergistic action with CsA, that permits lowering of the CsA dose, thereby decreasing its potential nephrotoxicity, is also seen using anti-TNF-α antibodies. Furthermore, it has been shown that combining anti-LT with anti-TNF-α...

| Table 3. Strategies interfering with cytokine effects |
| --- |
| **Modulator** | **Targets** | **References** |
| CsA, FK506 | IL-2 | 64 |
| Antibodies | IL-2, IFN-γ, TNF-α, TNF-β, IL-2R+ cells | 65-69, 76-85 |
| Cytokine conjugated toxins | IL-2R+ cells | 86, 87 |
| Soluble receptors | IL-1, IL-4 | 88, 89 |
| Cytokines (IL-4, IL-10) | Th2 subset | 98, Dallman et al. |
mAb ameliorates graft survival, compared with anti-TNF-α mAb treatment alone.66

Although these antibody treatments directed against single cytokines have some effect, graft survival times are not impressive. One of the reasons for this finding could be the property of cytokines to mediate local, i.e. in the graft, short-distance effects. Therefore the local antibody concentration might not be sufficient to neutralize its target cytokine. However, there is evidence that the neutralizing antibodies indeed reach the graft, since 125I-labelled anti-IL-2 mAb was detectable in the graft.66 Furthermore, local effects of the mAb, such as diminished mononuclear cell infiltration, no expression of MHC class I antigens and modification of immunohistologic staining pattern of TNF-α, were readily visible.676972 Another explanation for the disappointing results with cytokine-directed antibodies is the redundancy of the cytokine system. Neutralizing the activity of one cytokine probably makes another take over. The striking redundancy of the cytokine system was again demonstrated by the finding, that IL-2 and IL-4 knock-out mice were less affected in the development and function of their T cell system than expected.7374

Another approach to interfere in the cytokine network, by using mAb directed against the IL-2R (CD25), has been shown to be more successful. Not only the number of publications on the use of this mAb, but also the fact that this treatment is already used in clinical trials, are indicative for its success. Anti-IL-2R mAb therapy differs from anti-cytokine mAb therapy in that it acts on IL-2R bearing cells and not just on soluble proteins. Since high-affinity IL-2R is only expressed on activated T cells and not on resting T cells, this approach seems more specific than other established immunosuppressive therapies using ATG, OKT3 or CsA.75 The mechanism of the anti-IL-2R induced immunosuppression is still not clear. Depletion of IL-2R+ cells, modulation of the IL-2R or blocking of the IL-2-IL-2R interaction have been proposed to play a role.76-79 In animal models anti-IL-2R mAb have been used to inhibit GVHD and organ allograft rejection.767981 Prospective clinical trials have shown that anti-IL-2R treatment is equally effective as ATG for the prevention of renal allograft rejection.82-84

The use of mouse or rat mAb in clinical transplantation is hampered by the development of human anti-antibodies, that subsequently lead to high clearance rate of the mAb and abrogation of their effect. Therefore, 'humanized' mAb have been produced, combining the rodent complementarity-determining regions with constant regions and framework of human antibodies. A 'humanized' anti-IL-2R mAb, that was less immunogenic and had a longer half-life than its murine form, significantly prolonged cardiac allograft survival in cynomolgus monkeys.85 As 'humanized' mAb were being developed, molecular engineering offered an alternative approach for selectively attacking IL-2R+ cells. Cytotoxic substances, such as Pseudomonas exotoxin (PE) or Diphtheria toxin were coupled to IL-2, thereby targeting and killing IL-2R+ cells. IL-2-PE40 and DAB486-IL-2 were able to inhibit allograft survival in animal models.8687

**Soluble cytokine receptors:** In biological fluids of both animals and humans, cytokine binding proteins have been found, that later appeared to be soluble forms of cytokine receptors, like sIL-2R, sIL-4R and sTNFR. They generally have the same binding affinity for their ligand as the membrane receptors and therefore are able to competitively inhibit cytokine binding to membrane receptors and subsequently their effects on target cells. Soluble cytokine receptors are considered to be naturally occurring cytokine inhibitors and have the advantage of higher affinity and being non-immunogenic over neutralizing mAb. Their potential as therapeutic agents in inflammatory disease and sepsis has been shown. In a cardiac allograft model in mice, sIL-1R and sIL-4R have been shown to somewhat prolong the allograft survival.8889

The efficacy of treatment with soluble cytokine receptors is based on scavenging the relevant cytokine. Therefore, it is crucial to have the soluble cytokine receptor present in the serum with a long half-life. The linking of two sTNFR molecules to the Fc portion of a single human IgG1 molecule resulted in a dimeric form of sTNFR with significantly higher affinity for TNF than the monomeric sTNFR. Moreover, this complex is detectable in serum during 4-5 days, being significantly increased over unbound sTNFR. This dimeric sTNFR was very effective in *in vivo* neutralizing endogenous TNF and protecting mice from lethal endotoxaemia.90,91 Since anti-TNF mAb have been shown to be effective in prolonging allograft survival,9293 this agent might have a similar or even more potent effect on allograft rejection. Using soluble cytokine receptors, one should keep in mind that they are also capable of acting as cytokine carriers, protecting them from proteolytic cleavage, prolonging their half-life in the circulation and therefore having an agonistic instead of an antagonistic effect.92 The ratio in the presence of the cytokine and its soluble receptor probably determines the biological outcome.

**Strategies for Th1-Th2 skewing:** The assumption that Th1 cells are responsible for rejection, whereas Th2 cells may act as suppressor cells and induce graft acceptance has led to the idea that 'skewing' of the Th1-Th2 ratio towards Th2 dominance might inhibit graft rejection. *In vitro* studies have shown that cytokines can direct the differentiation of Th cells to one of the subsets. In the presence of IFN-γ Th1 cell development is enhanced,98 whereas IL-4 enhances
the development of Th2 cells. IL-10 does not seem to direct bulk cultures towards Th2 cytokine producing cells, though anti-IL-10 mAb did induce Th1-like cells. Treatment of allograft recipients with IL-4 or IL-10 could have the same 'skewing' effect. Furthermore, IL-10 not only inhibits the production of Th1 cytokines, but also has anti-inflammatory properties by inhibiting IL-1, IL-6 and TNF-α synthesis by macrophages. In vivo interference in the dominance of one of the Th subsets has already succeeded in a number of inflammatory models. Giving anti-IL-4 mAb before or within the first week of *Leishmania major* infection rendered a susceptible mouse strain resistant to the parasite, but anti-IL-10 mAb had no effect. The other way around, IL-4 promoted the Th2 response to the parasite, but did not render the infected recipient susceptible. Anti-IFN-γ mAb did render *Trypanosoma cruzi* resistant mice susceptible to the infection. In an allogeneic graft model, the use of anti-IFN-γ or anti-IL-2 mAb has not been very effective in prolonging allograft survival, as we described earlier. There have been two groups reporting on the effect of administration of Th2 cytokines, IL-4 and IL-10, on allogeneic responses. Though cardiac allograft rejection (M. Dallman, personal communication) and enlargement of the draining lymphnode were inhibited, no tolerance was induced. Furthermore, systemic administration of these cytokines could have some drawbacks, such as stimulation of B lymphocytes, antibody-production and increased incidence of infections. Also, there is evidence that systemic administration of cytokines, in this case IFN-γ, may lead to a downregulation of endogenously produced cytokine.

**Prospects for therapeutic strategies:**

Strategies directed against a single cytokine in the form of mAb, soluble cytokine receptors or other agents are not likely to be successful in inhibiting graft rejection. Molecular engineered proteins, on the other hand, such as the dimeric form of sTNFRI, may be useful to inhibit the intragraft inflammation and systemic effects of graft rejection. Other than in parasitic models, systemic administration of cytokines will probably not be able to interfere with the local processes leading to graft rejection. The increasing knowledge on requirements for T cell activation and the different signalling pathways leading to cytokine production and T cell subset activation, should enable us to interfere with this process in order to establish allospecific tolerance. T cell activation requires besides TcR-MHC interaction costimulatory signals coming from interaction of cell surface molecules on the APC and the T cells. Indeed, *in vitro* studies have shown that TcR signalling in the absence of costimulatory signals results in T cell anergy. Furthermore, this anergy can be induced in Th1 clones but not in Th2 clones. The CD28-B7 interaction seems to play a critical role in the costimulation of T cells. In *in vitro* blocking of this interaction inhibits cardiac allograft rejection and induces long term survival of pancreatic xenografts. Further studies in *in vitro* and animal models for tolerance should lead to strategies resulting in anergy of allospecific Th1 cells and induction of allospecific ‘suppressor’ Th2 cells and thereby to allospecific tolerance.

**Concluding remarks**

Cytokines are involved in the allograft rejection process. However, the relevance of systemic cytokine measurements in order to predict graft rejection is limited, since elevated cytokine levels are found both during rejection and infection. In the induction phase of rejection, a major role is probably played by IL-2 and IFN-γ together with or in balance with IL-4. During the effector phase, different cytokines may mediate the inflammation. The local rejection process is not easily inhibited by systemic administration of anti-cytokines or cytokines. Intervention in cellular signalling may lead to a new immunological balance and a state of graft tolerance, based on Th1 anergy and/or Th2 suppression.

**References**

1. Hayry P. Mechanisms of rejection. *Curr Opin Immunol* 1989; 1: 1220–1225.
2. Colvin RB. Cellular and molecular mechanisms of allograft rejection. *Annu Rev Med* 1990; 41: 561–575.
3. Wiede H, Aucottcros J. Cellular mechanisms of rejection. *Curr Opin Immunol* 1992; 4: 561–565.
4. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. *Ann Intern Med* 1990; 113: 619–627.
5. Strom TB. The cellular and molecular basis of allograft rejection: what do we know? *Transplant Proc* 1998; 30: 143–146.
6. Kaye J, Gillis S, Stuifl, et al. Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. *J Immunol* 1984; 133: 1359–1365.
7. Dunum SK, Schmidl JA, Oeppehen JH. Interleukin 1: an immunological perspective. *Annu Rev Immunol* 1985; 3: 265–287.
8. O’Garra A. Interleukins and the immune system I. *Lancet* 1989; 1: 943–947.
9. O’Garra A. Interleukins and the immune system 2. *Lancet* 1989; 1: 1003–1005.
10. Shalaby MR, Aggarwal BB, Biderkenoch E, Swedenky LP, Finkle BS, Palladino MA. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factor. *J Immunol* 1985; 135: 2069–2073.
11. Collins T, Lapierre R, Fans W, Strominger JI, Pober JS. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in *vivo*. *Proc Natl Acad Sci USA* 1990; 88: 446–450.
12. Tracey KJ, Vlassara H, Geraci A. Cachetkin/tumour necrosis factor. *Lancet* 1989; 1: 1122–1126.
13. Maessen JG, Bussmann WA, Koester G. Direct cytotoxic effect of cytokines in kidney parenchyma: a possible mechanism of allograft destruction. *Transplant Proc* 1990; 22: 709–710.
14. Mosmann TR, Garnham RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 1989; 7: 145–173.
15. Romagnani S. Human TH1 and TH2 subsets: doubt no more. *Immunol Today* 1991; 12: 256–257.
16. Gajewski TF, Pitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of T2 but not TH1 murine helper T lymphocyte clones. *J Immunol* 1988; 140: 4245–4252.
17. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. TH2 clones secrete a factor that inhibits cytokine production by TH1 clones. *J Exp Med* 1989; 170: 2081–2095.
18. Mosmann TR, Moore KJ. The role of IL-10 in crossregulation of TH1 and TH2 responses. *Immunol Today* 1991; 12: 49–53.
Cytokines in transplantation

19. Nguyen DT, Foland-Mk, DeFoe LG, et al. Cyclosporin A modulation of tumor necrosis factor gene expression and effects in vitro and in rats. J Immunol 1990; 144: 3822-3828.

20. Beuther F, Cerami A. Cachectin: than tumornecrosisfactor. N Engl J Med 1989; 327: 375-380.

21. Yoshimura N, Kahan BD, Oka T. The in vivo effect of cytosine arabinoside on interleukin-6 gene expression in renal transplant recipients. Transplant Proc 1991; 23: 1097-1101.

22. Abramowicz D, Schandene L, Goldberg M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 48: 606-608.

23. Yoshimura N, Oka T, Kahan BD. Sequential determinations of interleukin-6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Transplantation 1991; 51: 172-176.

24. De Robertis JM, Leoncin KM, van Hooff HJ, van der Linden CJ, Boorman WA. Evidence of involvement of tumor necrosis factor in adverse reactions during treatment of kidney allograft rejection with antithymocyte globulin. Transplantation 1989; 48: 467-472.

25. Van Oers MH, Van der Heyden AA, Aarden LA. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol 1988; 71: 314-319.

26. Kita Y, Iwaki Y, Demetris AJ, Starzl TE. Evaluation of sequential determinations of interleukin 2 receptor levels as indicator of rejection in renal allograft recipients. Transplant Proc 1989; 21: 125-129.

27. Simon MA, MacRae PN, Corally AJ, et al. Sequential determinations of urinary cytokine and plasma and urinary lymphokines in the management of renal allograft rejection. Transplant Proc 1989; 21: 218-223.

28. Cotter RF, Preffer FI, Fuller TC, et al. A critical analysis of andurine of renal transplant recipients. Clin Exp Immunol 1988; 71: 314-319.

29. Gascoigne AD, Shenton BK, White MD, Colquhoun IW, Dark JH, Corris PA. The role of soluble interleukin-2 receptor in kidney transplant rejection. Transplantation 1989; 47: 219-225.

30. Perkins JD, Nelson DE, Rakela J, Grambsch PM, Krom RA. Soluble interleukin-2 receptor levels as an indicator of allograft rejection. Transplantation 1989; 48: 77-81.

31. Humbert M, Emilie D, Cerrina J, et al. Soluble interleukin receptor and neopterin in renal allograft recipients. Transplant Proc 1989; 21: 125-129.

32. Invernizzi P, Beretta A, Fumagalli R, et al. Alpha interferon in renal allograft rejection. J Exp Med 1987; 166: 1132-1137.

33. Takeuchi T, Winder KL, Schleder W. Alpha interferon in human liver allograft rejection. Transplantation 1992; 53: 449-456.

34. Tono T, Monden M, Yoshizaki K, et al. Biliary interleukin 6 levels in liver allograft recipients. Transplantation 1994; 57: 219-225.

35. Tovey M, Gigou M, Gugenheim J, et al. Prolongation of heart allograft survival in rats. J Immunol 1990; 145: 4648-4650.

36. Takeuchi T, Ohsaki T, Ohnishi T, Saito S, Matsuoka J, Orita K. The effect of anti-CD4 monoclonal antibody on rejection of renal allografts. J Immunol 1990; 145: 283-286.

37. Sakagami K, Ohsaki T, Ohnishi T, Saito S, Konishi S, Fujimoto S. Adoptive transfer of a Th3-like cell line prolongs MHC class-II antigen disparate skin allograft survival in the mice. J Immunol 1993; 150: 855-862.

38. Bosset M, Huguenin PP. Competitive inhibition results from altered regulation of the interleukin 2 pathway. J Exp Med 1989; 173: 79-87.

39. Bogen I, Cuturi MC, Hallem MM, Painius J, Chabannes D, Soulier JP. Peripheral tolerance to allografts in adult rats - increased by irradiation and by treatment with antibody against T cell receptor. J Exp Med 1987; 166: 1132-1137.

40. Solter D, Friedman M, Ruddle FH. Antisense oligodeoxynucleotide to human interleukin-2 receptor alpha chain blocks interleukin-2 receptor expression on T cells. J Exp Med 1988; 168: 1132-1137.

41. Imagawa DK, Mills JM, Ollhoff KM, et al. Sequential analysis of IL-2 and IL-4 gene expression in renal allograft recipients. Transplant Proc 1991; 23: 683-685.

42. Gugenheim J, Tovey M, Gigou M, et al. Prolongation of heart allograft survival in rats. J Immunol 1990; 145: 4648-4650.

43. Gugenheim J, Tovey M, Gigou M, et al. Prolongation of heart allograft survival in rats. J Immunol 1990; 144: 4648-4650.

44. Sakagami K, Obashi T, Ohnishi T, Saito S, Miwa K, Orita K. The effect of anti-CD4 monoclonal antibody on rejection of renal allografts. J Immunol 1990; 144: 1308-1314.

45. Siegel A, Lehman M, Riedel H, et al. A nondepleting anti-CD4 monoclonal antibody that impairs T helper 1-like but not T helper 2-like cytokine secretion in vivo. J Immunol 1991; 147: 1133-1137.

46. Papp I, Winder KL, Schleder W. Evidence for functional heterogeneity of rat CD4+ T cells in vitro. Differential expression of IL-2 and IL-4 mRNA in recipients of cardiac allografts. J Immunol 1992; 148: 1304-1314.

47. Siegel A, Lehman M, Riedel H, et al. A nondepleting anti-CD4 monoclonal antibody that impairs T helper 1-like but not T helper 2-like cytokine secretion in vivo. J Immunol 1991; 147: 1133-1137.

48. Imagawa DK, Mills JM, Ollhoff KM, et al. The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphokine enhances cardiac allograft survival in rats. Transplantation 1990; 50: 189-193.

49. Takeuchi T, Takeda M, Tahashitsu S, Ogashi F, Fujimoto S. Adoptive transfer of a Th3-like cell line prolongs MHC class-II antigen disparate skin allograft survival in the mice. J Immunol 1994; 153: 855-862.

50. Dallman MJ, Skibo O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to alloantigens results from altered regulation of the interleukin 2 pathway. J Exp Med 1989; 173: 79-87.

51. Dallman MJ, Skibo O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to alloantigens results from altered regulation of the interleukin 2 pathway. J Exp Med 1989; 173: 79-87.
of the effectors mechanisms mediated by variant murine isotypes. *Transplant Proc* 1989; 21: 1005–1005.

78. Telledis D, Dallman MJ, Moriss PJ. Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (MAb) therapy: target cell depletion or inhibition of function? *Transplant Proc* 1989; 21: 997–998.

79. Kirkman RL, Barrett LV, Gauton GN, et al. The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection. *Transplantation* 1985; 40: 719–722.

80. Fermon JL, Martin A, McNulty JF, Murphy GF, Bunkoff SJ. Amelioration of acute graft vs host disease due to minor histocompatibility antigens by its into administration of anti-interleukin 2 receptor antibody. *J Immunol* 1986; 137: 1874–1877.

81. Diamantstein T, Mouzaki A, Osawa H, et al. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunoablation. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A. *Deb Biol Stand* 1988; 69: 177–184.

82. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. *Transplantation* 1991; 51: 107–113.

83. Soulillou JP, Centurion D, Le Masurier B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts (see comments). *N Engl J Med* 1990; 322: 1175–1182.

84. Hesse C, Kries P, Abert P, et al. Prophylactic use of the IL-2 receptor-specific monoclonal antibody L2-Tac-1 with cyclosporin A and steroids in renal transplantation. *Transplant Rev* 1992; 5 (Suppl 1): 5444–5447.

85. Brown PSJ, Parenteau GL, Dirbas FM, et al. Anti-Tac-H, humanized antibody to the interleukin receptor, prolongs primate cardiac allograft survival. *Proc Natl Acad Sci USA* 1991; 88: 2663–2667.

86. Hang F, Todek HA, Marsters SA, et al. Inhibition of TNF by TNF receptor immunoadhesion. *Comparisons to anti-TNF monoclonal antibody. Proc Natl Acad Sci USA* 1989; 86: 1008–1012.

87. Tellides G, Dallman MJ, Morris PK. Mechanism of action of interleukin-2 receptor. *Adv Exp Med Biol* 1991; 292: 167–176.

88. Jenkins MK, Johnson PG. Molecules involved in T-cell costimulation. *Curr Opin Immunol* 1993; 5: 747–752.

89. Jenkins MK, Pardoll DM, Schwartz RH, et al. Induction and maintenance of anergy in mature T cells. *Adv Exp Biol Med* 1991; 292: 167–176.

90. Jenkins MK, Johnson PG. Molecules involved in T-cell costimulation. *Curr Opin Immunol* 1993; 5: 361–367.

91. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.

92. Jenkins MK, Mueller D, Schwartz RH, et al. Induction and maintenance of anergy in mature T cells. *Adv Exp Biol Med* 1991; 292: 167–176.

93. Jenkins MK, Muller D, Schwartz RH, et al. Induction and maintenance of anergy in mature T cells. *Adv Exp Biol Med* 1991; 292: 167–176.

94. Jenkins MK, Pallod DM, Mizuguchi J, Chused TM, Schwartz RH. Molecular events required for TCR-mediated anergy in resting T lymphocytes and T cell clones. *Current Opinion in Immunology* 1993; 5: 58–61.

95. Jenkins MK, Pallod DM, Mizuguchi J, Chused TM, Schwartz RH. Molecular events in the induction of a nonresponder state in interleukin 2-producing helper T lymphocyte clones. *Proc Natl Acad Sci USA* 1987; 84: 5459–5463.

96. Williams MB, Scau CM, Lichman AH, Abbas AK. Antigen receptor-mediated anergy in resting T lymphocytes and T cell clones. *Current Opinion in Immunology* 1993; 5: 58–61.

97. Busch H, Linsley PS, Coffman RL. IL-4 induces Th2 response in Leishmania major-infected mice. *J Immunol* 1992; 149: 1182–1187.

98. Busch H, Linsley PS, Coffman RL. IL-4 induces a Th2 response in Leishmania major-infected mice. *J Immunol* 1992; 149: 1182–1187.

99. Busch H, Linsley PS, Coffman RL. IL-4 induces a Th2 response in Leishmania major-infected mice. *J Immunol* 1992; 149: 1182–1187.

100. Busch H, Linsley PS, Coffman RL. IL-4 induces a Th2 response in Leishmania major-infected mice. *J Immunol* 1992; 149: 1182–1187.

101. Busch H, Linsley PS, Coffman RL. IL-4 induces a Th2 response in Leishmania major-infected mice. *J Immunol* 1992; 149: 1182–1187.

102. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.

103. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.

104. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.

105. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.

106. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.

107. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.

108. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.

109. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.

110. Schwartz RH. A cell culture model for T lymphocyte clonal energy. *Science* 1990; 24: 1349–1356.